Elvitegravir

GlobalData report, "HIV / AIDS - Drug Pipeline Analysis and Forecasts to 2016" is an essential source of information and analysis on the global HIV / AIDS market. The report identifies key trends profiling and lead the fight against HIV / AIDS market. The report also gives an overview of the prevailing competitive landscape and emerging players should bring significant changes in the market position of existing market leaders. More importantly, the report provides valuable information on products in the pipeline global HIV / AIDS sector. GlobalData estimated that HIV / AIDS market was worth $ 12 billion in 2009. The global human immunodeficiency virus (HIV) infection, the market will continue to grow between 2009 and 2016 at a slower pace due to a series of patent expirations during this period. The growth rate is likely to decrease from 2012 due to the impact of patent expiry essential medicines. The market is characterized by high unmet demand for drugs that can cure the disease. Highly active antiretroviral therapy (HAART), which requires patients to take various classes of drugs has been managed to reach levels close to zero of HIV infected individuals. Increased use of HAART and awareness (leading to increased treatment research) will lead the market. The pipeline for HIV is high and consists of over 250 molecules currently in development for segments of various diseases.

This report is built using data and information from proprietary databases, the primary and secondary research and analysis GlobalData internal team of specialists in the industry.

Scope

- Annualized global HIV / AIDS market income data from 2001 to 2009, forecasts for the seven years to 2016.
- Geographies covered in this report are the United States (U.S.), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- The data analysis pipeline providing a split between the phases through a mechanism of action, and emerging trends. Classes key mechanism of action include vaccines against HIV, non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PI), multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), CCR5 receptor antagonists, inhibitors of HIV integrase, the nucleoside analogues, viral entry inhibitors, maturation inhibitors and fusion inhibitors.
- Analysis of competition in existing markets and future in the fight against HIV / AIDS market. The key market players covered Boehringer Ingelheim Pharmaceuticals Achillion, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco
- Review in depth the key drivers of the sector, constraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key themes include strategic competitor assessment, characterization of the market, unmet needs and future implications of HIV / AIDS market.

Reasons to buy

The report will improve your ability to take decisions in a more rapid and more sensitive to delays. It will:
- Develop and design of your license and licensing strategies for the study of goods in process and technology and identifying companies with the most robust pipeline.
- Develop strategies undertaken by the trends that shape and conduct the fight against HIV / AIDS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies that could impact the global HIV / AIDS in the future market.
- Formulate sales and marketing strategies that work by understanding the competitive environment and analyzing the performance of different competitors.
- Identify emerging players with potentially strong product portfolio and create strategies to win-cons COMPETITIV.